Material Overview: Properties of Glass and Plastic in Pharma

Glass: Glass, particularly Type I borosilicate, is chemically inert, impermeable, and thermally stable. It’s widely used in parenteral packaging and products with high sensitivity.

Plastic: Common plastics include HDPE, PET, and PP. They offer lighter weight and better resistance to breakage but are more permeable to gases and moisture.

• Glass is suitable for high-risk, injectable formulations
• Plastic is preferred for solid or oral liquid dosage forms

Chemical Compatibility and Reactivity

One of the most critical selection criteria is the interaction between the container and the drug product. Glass is non-reactive but may release trace alkali (in Type II or III) in some conditions. Plastic, on the other hand, may:

• Leach additives (plasticizers, antioxidants)
• Absorb or adsorb active ingredients
• React with solvents or volatile excipients

Compatibility studies are essential regardless of the material type. Testing should include leachables, extractables, and sorption assessments.

Barrier Properties: Moisture and Oxygen Transmission

Moisture ingress and oxygen permeability are major concerns during long-term storage.

• Glass: Offers complete barrier protection against water vapor and oxygen
• Plastic: Materials like HDPE have relatively high WVTR (water vapor transmission rate), while PET has better barrier properties

For sensitive formulations, glass or multilayer plastic with barrier coatings is preferred. Use appropriate desiccants in plastic packaging to reduce moisture uptake risk.

Mechanical Durability and Breakage Risk

Glass is fragile and prone to breakage during transport or handling, especially in high-speed filling lines or drop tests. Plastic is:

• Impact-resistant
• Lighter in weight
• Less costly to ship and store

For pediatric, geriatric, or field-use products, plastic often enhances patient and packaging safety.

Photostability and Light Protection

Amber glass provides high UV protection, making it ideal for photolabile drugs. In contrast:

• Plastic may need additional pigments or UV-blocking agents
• Opaque polymers (like black HDPE) are used when UV exposure is critical

Ensure ICH Q1B photostability testing is performed with final container type to evaluate light-related degradation risk.

Case Study: Vitamin Solution in PET vs. Glass

In a comparative study, a multivitamin oral solution stored in PET bottles showed 7% degradation at 3 months (40°C/75% RH), while the same product in amber Type I glass retained 98% potency. The oxygen permeability of PET contributed to oxidative degradation. Result: manufacturer switched to glass for final packaging.

Regulatory Expectations and Submission Impact

According to CDSCO and ICH, packaging used in stability must reflect the marketed pack. Regulatory agencies expect:

• Extractables and leachables studies for plastic
• Glass delamination risk assessment (for glass)
• Material specification sheets and compliance (e.g., USP for plastic)
• Photostability, integrity, and aging data

Failure to justify container type can delay approvals or prompt deficiency letters.

Environmental Impact and Sustainability Considerations

As sustainability becomes a regulatory and market priority, container material choice also reflects environmental responsibility.

• Glass: 100% recyclable, inert, and reusable—but energy-intensive to produce
• Plastic: Lower energy production cost but may generate microplastics and requires recycling infrastructure

Some companies opt for bio-based plastics or recyclable HDPE as a sustainable alternative when stability allows.

Cost and Supply Chain Factors

Cost can be a deciding factor when technical performance is equivalent:

• Plastic containers generally cost less in manufacturing and transportation
• Glass containers require specialized handling, packaging, and higher QA oversight
• Long lead times and regional supply dependencies can affect availability of both materials

Balance between cost and compliance is essential—cutting costs at the expense of protection often leads to regulatory delays.

When to Use Glass Over Plastic

• Parenteral dosage forms
• Highly moisture- or oxygen-sensitive APIs
• Long shelf-life products requiring complete barrier protection
• Regulatory submissions where robust data is essential

When Plastic Is a Better Choice

• Oral liquids or tablets with moderate sensitivity
• Patient-friendly packaging needs (e.g., squeezability, safety)
• Field or ambulatory settings with rough handling
• Cost-sensitive generics or short-shelf-life products

Stability Study Design: Considerations for Both Materials

Whether using glass or plastic, follow these best practices:

• Test containers under ICH long-term and accelerated conditions
• Include photostability and CCI tests in validation
• Conduct migration and sorption studies
• Ensure sealing compatibility with closures
• Perform mechanical testing under simulated transport stress

Refer to GMP guidelines to align packaging qualification with regulatory expectations.

Summary Comparison Table

Conclusion

Choosing between glass and plastic containers for long-term pharmaceutical storage requires a nuanced understanding of product properties, regulatory expectations, and logistical challenges. While glass offers unmatched protection and regulatory acceptance, plastic provides practical benefits in cost and safety. The right decision depends on balancing technical performance with compliance, sustainability, and patient use requirements.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Plastic Packaging Systems
• USP : Assessment of Extractables
• FDA Guidance for Industry: Container Closure Systems
• WHO Guidelines on Packaging Materials for Pharmaceuticals